Related Experiment Video
Updated: Jan 15, 2026

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess
Published on: June 1, 2022
Defining the action spectrum of potential PGC-1α activators on a mitochondrial and cellular level in vivo
Annette Hofer1, Natalie Noe, Christin Tischner
1Institute for Genetics and Cluster of Excellence: Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Zülpicher Str. 47A, 50674 Cologne, Germany.
Abstract:
Previous studies have demonstrated a therapeutic benefit of pharmaceutical PGC-1α activation in cellular and murine model of disorders linked to mitochondrial dysfunction. While in some cases, this effect seems to be clearly associated with boosting of mitochondrial function, additional alterations as well as tissue- and cell-type-specific effects might play an important role. We initiated a comprehensive analysis of the effects of potential PGC-1α-activating drugs and pharmaceutically targeted the PPAR (bezafibrate, rosiglitazone), AMPK (AICAR, metformin) and Sirt1 (resveratrol) pathways in HeLa cells, neuronal cells and PGC-1α-deficient MEFs to get insight into cell type specificity and PGC-1α dependence of their working action. We used bezafibrate as a model drug to assess the effect on a tissue-specific level in a murine model. Not all analyzed drugs activate the PGC pathway or alter mitochondrial protein levels. However, they all affect supramolecular assembly of OXPHOS complexes and OXPHOS protein stability. In addition, a clear drug- and cell-type-specific influence on several cellular stress pathways as well as on post-translational modifications could be demonstrated, which might be relevant to fully understand the action of the analyzed drugs in the disease state. Importantly, the effect on the activation of mitochondrial biogenesis and stress response program upon drug treatment is PGC-1α dependent in MEFs demonstrating not only the pleiotropic effects of this molecule but points also to the working mechanism of the analyzed drugs. The definition of the action spectrum of the different drugs forms the basis for a defect-specific compensation strategy and a future personalized therapeutic approach.
Insights
Pharmaceuticals activating Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) show therapeutic benefits for mitochondrial dysfunction. This study reveals drug- and cell-specific effects, highlighting PGC-1α
Area of Science:
- Biochemistry
- Cell Biology
- Pharmacology
Background:
- Previous studies indicate therapeutic benefits of pharmaceutical Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) activation in mitochondrial dysfunction disorders.
- The precise mechanisms and cell-type specificity of these effects require comprehensive investigation.
Purpose of the Study:
- To analyze the cell-type specificity and PGC-1α dependence of drugs targeting PPAR, AMPK, and Sirt1 pathways.
- To elucidate the impact of these drugs on cellular stress pathways and protein stability.
Main Methods:
- Utilized HeLa cells, neuronal cells, and PGC-1α-deficient mouse embryonic fibroblasts (MEFs).
- Administered drugs targeting PPAR (bezafibrate, rosiglitazone), AMPK (AICAR, metformin), and Sirt1 (resveratrol).
- Assessed effects on mitochondrial function, OXPHOS complex assembly, protein stability, cellular stress pathways, and post-translational modifications.
- Employed a murine model to evaluate tissue-specific effects of bezafibrate.
Main Results:
- Not all drugs activated PGC-1α or altered mitochondrial protein levels, but all affected OXPHOS complex assembly and protein stability.
- Demonstrated drug- and cell-type-specific influences on cellular stress pathways and post-translational modifications.
- Confirmed PGC-1α dependence of mitochondrial biogenesis and stress response activation in MEFs.
Conclusions:
- Drug-induced mitochondrial biogenesis and stress response are PGC-1α dependent, indicating pleiotropic effects of PGC-1α.
- The findings provide insights into the working mechanisms of PGC-1α-activating drugs.
- This research lays the groundwork for defect-specific compensation strategies and personalized therapeutic approaches.
More Related Videos
Related Concept Videos
GPCRs Regulate Adenylyl Cylase Activity
cAMP-dependent Protein Kinase Pathways
Activation and Inactivation of G Proteins
Energy to Drive Translocation
Generally, polypeptides are unfolded by two distinct...
Cell Specific Gene Expression

